作者: Maria GL Brandão , Gustavo P Cosenza , Acácia M Stanislau , Geraldo W Fernandes , None
DOI: 10.1007/S10661-009-0899-4
关键词:
摘要: For decades, several native medicinal species have been used by the pharmaceutical industry in Brazil to create commercial products. In 1995, Ministry of Health, following recommendations World Health Organization, established herbal regulations (RDC 17) order improve quality such fact, only plant with conclusive results from pharmacological and toxicological studies can be for creating medicines. this study, we evaluated consequences RDC 17 on use conservation plants comparing material six companies 1995/1996 10 years later (2005/2006). Eighty-three different were 1995/1996, 50 them (60.2%), 16 exotic (19.3%), imported (20.5%). 2005/2006, 44 19 (43.2%) native. The category that saw largest decrease was roots, 2005/2006 leaves more used. study shows a strong reduction collection signalizing importance their conservation. It also points need Brazilian flora, as well ecology